跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
AT-193
首页
药物
AT-193
AT-193
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Dominant negative SARM1 molecules comprising a substitution at position 189, 190, 193, 194, 570 and/or 685 of SARM1
申请人: WASHINGTON UNIVERSITY ST LOUIS
优先权: 2018
US
Photoresist resin monomer with adamantane structure and synthesis method thereof
申请人: SHANGHAI BNCSCITECH CO LTD
优先权: 2020
CN
Imide sulfo N-hydroxy maleopimarate as light acid producing agent and its synthetic method
申请人: UNIV BEIJING NORMAL
优先权: 2004
CN
Cyclic sulfonium and sulfoxonium photoacid generators and photoresists comprising same
申请人: CAMERON JAMES F
优先权: 2002
US
Photoresist polymer and photoresist composition containing the same
申请人: HYNIX SEMICONDUCTOR INC
优先权: 2003
US
2 件公开
Oxime sulfonate and N-oxyimidosulfonate photoacid generators and photoresists comprising same
申请人: SHIPLEY CO LLC
优先权: 2000
US
COMPOSITIONS FOR P65 INHIBITION AND METHODS OF USE THEREOF
申请人: ALTAMIRA THERAPEUTICS AG
优先权: 2024
WO
Bacterical/permability-increasing protein(BPI) deletion analogs
申请人: HORWITZ ARNOLD
优先权: 2000
US
2 件公开
药物
反馈